Previous Page
Researchers concluded that the test, which required less than 5 minutes of user hands-on time, provided accurate organism identification and detection of resistance Staphylococcus aureus or S. epidermidis. Researchers concluded that the test, which required less than 5 minutes of user hands-on time, provided accurate organism identification and detection of resistance genes compared to routine laboratory methods.
Nanostart Asia Pacific is preparing an additional fundraising of up to 4 million SGD for its further expansion. A large part of the amount has already been committed. As in the previous funding in February 2012, the money comes from the existing shareholders and new investors based in the region. It shall be used for follow up funding the existing portfolio. Furthermore Nanostart Asia Pacific is already working on new investment opportunities.
In addition the company has formed an advisory board with renowned experts in order to support the further development of the company. The board will initially comprise of Harry De Wit, President Asia with Covidien, Prof. Dr. Uwe Klima, Head of Cardiosurgery at the American Hospital Dubai, Günter Mayer, Senior Manager with Infineon, Jürgen Binzer, Entrepreneur and Vice President with Hollingsworth & Vose in Germany and Chua Hong Moh, Entrepre- neur from Singapore. The advisors will support the company’s further development and its expansion in Asia by providing their expertise as well as their broad network.
The announcement is made during the event "Investing in Singapore Nanotechnology" at Singapore Polytechnic, where Nanostart Asia Pacific and Sin- gapore Polytechnic jointly feature their activities in the nano- and high-tech space to the investment and business community.
Nanostart-holding ItN Nanovation AG has successfully completed the capital increase announced on September 12. By placing 838,964 new shares among existing shareholders, a net value of nearly 1.2 million euros will flow into the company. The issue price was determined in direct juxtaposition to the stock market price, as the legal right to purchase was excluded. The capital increase raises the share capital of ItN Nanovation to 11,832,766 euros. The incoming funds will serve to strengthen the equity capital of the company.
http.//www.itn-nanovation.de http://nanostart.de/
NanoString Technologies, Inc., has obtained the CE Mark for its PAM50-based gene expression test for breast cancer, clearing the company to sell its test in the European Union and other countries recognizing the CE Mark. NanoString’s test provides a subtype classification based on the fundamental biology of an individual’s breast tumor (referred to as intrinsic subtyping), as well as a prognostic score that predicts the probability of cancer recurrence over 10 years in post-menopausal women with hormone receptor-positive, early stage breast cancer (ESBC) who have been treated with hormonal therapy.